OR32. Efficacy and Safety of Therapeutic Versus Prophylactic Dose of Anticoagulation in Hospitalized Patients with Severe COVID-19 Pneumonia and Coagulopathy: An Open-Label, Randomized Controlled Trial

被引：0
|
作者：
Adrian, L. H. [1 ]
Hutomo, S. A. [1 ]
Negari, A. D. S. [1 ]
机构：
[1] Syarifah Ambami Rato Ebu Gen Hosp, Dept Cardiol & Vasc Med, East Java, Indonesia
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2021年 / 23卷 / SUPPL F期
关键词：
COVID-19; coagulopathy; therapeutic; anticoagulant; efficacy; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Therapeutic Versus Prophylactic Dose of Anticoagulation in Hospitalized Patients with Severe COVID-19 Pneumonia and Coagulopathy: An Open-Label, Randomized Controlled Trial
    Adrian, L. H.
    Hutomo, S. A.
    Negari, A. D. S.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0F)
  • [2] Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial
    Marcos-Jubilar, Maria
    Carmona-Torre, Francisco
    Vidal, Rosa
    Ruiz-Artacho, Pedro
    Filella, David
    Carbonell, Cristina
    Jimenez-Yuste, Victor
    Schwartz, Juana
    Llamas, Pilar
    Alegre, Felix
    Sadaba, Belen
    Nunez-Cordoba, Jorge
    Yuste, Jose R.
    Fernandez-Garcia, Javier
    Lecumberri, Ramon
    THROMBOSIS AND HAEMOSTASIS, 2022, 122 (02) : 295 - 299
  • [3] Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
    Rahhal, Alaa
    Najim, Mostafa
    Aljundi, Amer Hussein
    Mahfouz, Ahmed
    Alyafei, Sumaya Mehdar
    Awaisu, Ahmed
    Habib, Mhd Baraa
    Obeidat, Ibrahim
    Faisal, Mohanad Mohammed
    Alanzi, Meshaal Ali
    Nair, Arun Prabhakaran
    Elhassan, Areeg
    Al-Dushain, Abdullah
    Abdelmajid, Alaaeldin Abdelmajid
    Abdelgader, Ahmed Elfadil
    Moursi, Ahmed Mahmoud Ahmed
    Alharafsheh, Ahmad Eid Nazzal
    Abou Kamar, Mohd Ragheb
    Goravey, Wael
    Omar, Amr Salah
    Abukhattab, Mohammed
    Khatib, Mohamad Yahya
    Mohamedali, Mohamed Gaafar
    AlMaslamani, Muna A. Rahman
    Alemadi, Samar
    MEDICINE, 2022, 101 (39) : E30618
  • [4] Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
    Begin, Philippe
    Callum, Jeannie
    Jamula, Erin
    Cook, Richard
    Heddle, Nancy M.
    Tinmouth, Alan
    Zeller, Michelle P.
    Beaudoin-Bussieres, Guillaume
    Amorim, Luiz
    Bazin, Renee
    Loftsgard, Kent Cadogan
    Carl, Richard
    Chasse, Michael
    Cushing, Melissa M.
    Daneman, Nick
    Devine, Dana, V
    Dumaresq, Jeannot
    Fergusson, Dean A.
    Gabe, Caroline
    Glesby, Marshall J.
    Li, Na
    Liu, Yang
    McGeer, Allison
    Robitaille, Nancy
    Sachais, Bruce S.
    Scales, Damon C.
    Schwartz, Lisa
    Shehata, Nadine
    Turgeon, Alexis F.
    Wood, Heidi
    Zarychanski, Ryan
    Finzi, Andres
    Arnold, Donald M.
    NATURE MEDICINE, 2021, 27 (11) : 2012 - +
  • [5] Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial
    Perepu, Usha S.
    Chambers, Isaac
    Wahab, Abdul
    Ten Eyck, Patrick
    Wu, Chaorong
    Dayal, Sanjana
    Sutamtewagul, Grerk
    Bailey, Steven R.
    Rosenstein, Lori J.
    Lentz, Steven R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (09) : 2225 - 2234
  • [6] Safety and Efficacy of Interferon β-1b in the Treatment of Severe COVID-19 Patients: An Open-Label Randomized Controlled Trial
    Moazen, Javad
    Masoudiyekta, Leila
    Kassani, Aziz
    Mohseni, Seifollah
    Mirsamiyazdi, Nastaran
    Nosratabadi, Mahnaz
    Mehranfard, Shahzad
    Rezaei-Bayatiyani, Hojat
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2022, 17 (05):
  • [7] Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
    Bertoldi Lemos, Anna Cristina
    do Espirito Santo, Douglas Alexandre
    Salvetti, Maisa Cabetti
    Gilio, Renato Noffs
    Agra, Lucas Barbosa
    Pazin-Filho, Antonio
    Miranda, Carlos Henrique
    THROMBOSIS RESEARCH, 2020, 196 : 359 - 366
  • [8] Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, Open-label, Controlled Clinical Trial
    Tehrani, Shabnam
    Yadegarynia, Davood
    Bagherzade, Afshin
    Gachkar, Latif
    Keyvanfar, Amirreza
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2022, 11
  • [9] Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    De Leeuw, Elisabeth
    Van Damme, Karel F. A.
    Declercq, Jozefien
    Bosteels, Cedric
    Maes, Bastiaan
    Tavernier, Simon J.
    Detalle, Laurent
    Smart, Trevor
    Glatt, Sophie
    Debeuf, Nincy
    Deckers, Julie
    Lameire, Sahine
    Vandecasteele, Stefaan J.
    De Neve, Nikolaas
    Demedts, Ingel K.
    Govaerts, Elke
    Knoop, Christiane
    Vanhove, Karolien
    Moutschen, Michel
    Terryn, Wim
    Depuydt, Pieter
    Van Braeckel, Eva
    Haerynck, Filomeen
    Hendrickx, Tine C. J.
    Parrein, Vanessa
    Lalla, Marianna
    Brittain, Claire
    Lambrecht, Bart N.
    RESPIRATORY RESEARCH, 2022, 23 (01)
  • [10] Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
    Elisabeth De Leeuw
    Karel F. A. Van Damme
    Jozefien Declercq
    Cedric Bosteels
    Bastiaan Maes
    Simon J. Tavernier
    Laurent Detalle
    Trevor Smart
    Sophie Glatt
    Nincy Debeuf
    Julie Deckers
    Sahine Lameire
    Stefaan J. Vandecasteele
    Nikolaas De Neve
    Ingel K. Demedts
    Elke Govaerts
    Christiane Knoop
    Karolien Vanhove
    Michel Moutschen
    Wim Terryn
    Pieter Depuydt
    Eva Van Braeckel
    Filomeen Haerynck
    Tine C. J. Hendrickx
    Vanessa Parrein
    Marianna Lalla
    Claire Brittain
    Bart N. Lambrecht
    Respiratory Research, 23
12345